DrugPatentWatch Database Preview
Drugs in Development Information for Trebananib
» See Plans and Pricing
What is the development status for investigational drug Trebananib?
Trebananib is an investigational drug.
There have been 8 clinical trials for Trebananib.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2011.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Renal Cell, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are Amgen, National Cancer Institute (NCI), and Roswell Park Cancer Institute.
There are two US patents protecting this investigational drug and two international patents.
Summary for Trebananib
| US Patents | 2 |
| International Patents | 2 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2011-03-01) |
| Vendors | 0 |
Recent Clinical Trials for Trebananib
| Title | Sponsor | Phase |
|---|---|---|
| Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Amgen | Phase 1 |
| Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Merck Sharp & Dohme Corp. | Phase 1 |
| Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Dana-Farber Cancer Institute | Phase 1 |
Clinical Trial Summary for Trebananib
Top disease conditions for Trebananib
Top clinical trial sponsors for Trebananib
US Patents for Trebananib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Trebananib | Start Trial | Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane | Amgen Inc. (Thousand Oaks, CA) | Start Trial |
| Trebananib | Start Trial | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients | Corning Incorporated (Corning, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Trebananib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Trebananib | World Intellectual Property Organization (WIPO) | WO2016176427 | 2035-04-30 | Start Trial |
| Trebananib | European Patent Office | EP2796427 | 2033-04-24 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
